Navigation Links
HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University
Date:6/8/2009

SAN DIEGO, June 8 /PRNewswire/ -- HUYA Bioscience International, a leader in enabling and accelerating the global co-development of novel biopharmaceutical product opportunities originating in China, today announced a strategic drug co-development partnership with the Shenyang Pharmaceutical University. The agreement covers a wide range of therapeutic areas and represents one of the first official collaborations of its kind between a U.S. biotech company and a Chinese university.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new pre-clinical and clinical stage compounds. The agreement with Shenyang Pharmaceutical University provides HUYA with rights of first review and negotiation relating to certain novel therapeutic compounds owned or controlled by the University. In return, Shenyang Pharmaceutical University gains access to HUYA's global network of pharmaceutical partners and its expertise in pre-clinical and clinical development.

"Shenyang Pharmaceutical University is a leading pharmaceutical institution with a tradition of innovation," said Mireille Gingras, PhD, President and CEO of HUYA. "We are enthusiastic about collaborating with this University to develop new products for global markets."

Enhancing its collaboration with Shenyang Pharmaceutical University, HUYA has key partnerships with leading global pharmaceutical companies such as Solvay Pharmaceuticals, Abbott, and Schering-Plough. By establishing an extensive global network and world-class drug development capabilities HUYA has become the partner-of-choice for Chinese institutions, universities and biopharma companies looking to maximize the value of their pre-clinical and clinical stage drugs for global markets. HUYA has acquired the development and commercialization rights to two novel development stage drug candidates sourced from China and is developing these candidates in the U.S. for cardiovascular and oncology indications.

"Through our partnership with HUYA, Shenyang Pharmaceutical University looks forward to expanding our international collaborations and gaining broader access to the worldwide markets for our innovative products," said Dr. Shunkai Bi, Vice President of Shenyang Pharmaceutical University.

About HUYA Bioscience International

HUYA Bioscience International is a leader in enabling and accelerating the global co-development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese academic and commercial biopharmaceutical organizations to enhance development efficiency and value creation in world-wide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the worldwide value of biopharmaceutical innovation in China. HUYA is jointly headquartered in San Diego, CA, and Shanghai, PRC. Additional information about the company is available at www.huyabio.com.

About Shenyang Pharmaceutical University

The Shenyang Pharmaceutical University has the longest tradition among China's pharmaceutical universities. It was founded in 1931, and now has over 260 professors and associate professors, over a quarter of who are overseas returnees. It is a national leader in the synthesis and screening of novel pharmaceutical compounds, pharmaceutical formulation development and evaluation, pharmacokinetics and pharmacodynamics, pharmacology and toxicology, and identification and purification of active ingredients from Traditional Chinese Medicines and natural products.

    Contact:

    USA:                               China:
    Bob Giargiari                      Li Zhu, PhD
    EVP Finance and CFO                VP China Operations
    HUYA Bioscience International,     HUYA Bioscience International,
    LLC                                LLC
    (858) 798-8800                     86 (21) 51323312
    bgiargiari@huyabio.com             lzhu@huyabio.com

    Media Contact:

        Juliet Travis
        (510) 452-3771
        juliet@travispr.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017  ArmaGen, Inc., today announced that it ... chief executive officer, as well as a member ... ArmaGen more than 17 years of executive management ... biotherapeutics and pharmaceuticals. "Mathias is ... and skillset necessary to lead ArmaGen to its ...
(Date:1/19/2017)... ... , ... FireflySci Inc. is a go-getter type of company that continues to ... two main factors. The first is the amazing customer service that the FireflySci ... all around the world. , 2016 was a tremendous sales year for FFS and ...
(Date:1/19/2017)... 18, 2017 Acupath Laboratories, Inc., a leading ... of an Executive Committee that will guide the company,s ... John Cucci , a 15-year veteran of the ... Business Development to Chief Sales Officer .  Prior ... in senior sales leadership roles at several leading lab ...
(Date:1/18/2017)... --  Boston Biomedical , an industry leader in the ... pathways, will feature data from two clinical studies for ... Gastrointestinal Cancers Symposium, held from January 19-21, in ... is an orally-administered investigational agent designed to inhibit cancer ... cells (CSCs) possess the property of stemness – the ...
Breaking Biology Technology:
(Date:1/3/2017)... Onitor, provider of digital health technology for ... innovative biometric data-driven program designed to aid weight loss ... 2017 Consumer Electronics Show (CES) in Las ... the World Health Organization (WHO), have identified lifestyle risks ... are overweight or obese. WHO also states that more ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
Breaking Biology News(10 mins):